The Vaccine Innovation Center at Korea University College of Medicine has been selected by the Korea Disease Control and ...
Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...
VERAXA Biotech (NASDAQ: VRXA) provided a corporate and pipeline update highlighting progress during the first half of 2026, ...
A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today ...
Ahmedabad: The analysis of antimicrobial resistant (AMR) organisms identified by the state-based institutions indicated that ...
Montpellier, France-based aquatic restoration engineering company Ecocean and Dendermonde, Belgium-based biotechnology ...
(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...
Healthcare stocks are attractive in a choppy market. These funds, focusing on the broader sector, drugmakers, and biotechs, ...
Novartis (NYSE: NVS) is paying $1.1 billion upfront to buy Myricx Bio, a London-based biotech with its U.S. presence based in ...
Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global ...
Investor's Business Daily on MSN
This profitable autoimmune biotech trades near a high and a buy point
This profitable Netherlands-based biotech name has produced triple-digit quarterly earnings growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results